A strategy for studying rare cancer phenotypes

A strategy for studying rare cancer phenotypes

The partnership and technologies developed by Cure First, SEngine Precision Medicine, in collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine, led to a seminal study in prostate cancer. Personalized cancer models from patients were developed and novel therapeutic combinations discovered and validated.

Mendelspod Podcast

Mendelspod Podcast

Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine

AACR - Chicago

AACR - Chicago

SEngine team presenting five posters at American Association for Cancer Research annual conference.

The Society for Functional Precision Medicine

The Society for Functional Precision Medicine

Got f(x)? Join The Society for Functional Precision Medicine (SFPM) and help advance the science and medicine of direct functional testing of patient cancer cells. SFPM's mission is to facilitate implementation of functional assays into clinical care.

SEngine + Fred Hutch

SEngine + Fred Hutch

SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center

Cancer Discovery Spotlight

A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery May 2017 PMID_28461408

CLIA certification in the news

CLIA certification in the news

SEngine CLIA certification makes the P.A.R.I.S. cancer test available to patients. The P.A.R.I.S. Assay employs live cancer cells to evaluate the response to >120 drugs on a given patient cancer sample in a matter of few weeks. 

GeekWire: How SEngine Tackles and Innovates Precision Medicine

GeekWire: How SEngine Tackles and Innovates Precision Medicine

There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.